Stable Formulation of Nerve Agent Intoxication Countermeasures
Award amount
$149,997Program and phase
SBIR · Phase IAward year
2019Award details
- Awarding agency
- Department of Defense
- Branch
- Office for Chemical and Biological Defense
- Recipient company
- LUNA INNOVATIONS INCORPORATED
- Proposal award date
- 2018-10-01
- Contract end date
- 2019-03-31
- UEI
- SJHFCDGKJJC5
- Solicitation number
- 18.1
- Topic code
- CBD181-005
Research abstract
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Preclinical Development of a Stable Atropine-Scopolamine Dual Formulation for Medical Countermeasure Readiness
- Dual Formulation of Atropine/Scopolamine with Enhanced Stability
- Dual Formulation of Atropine-Scopolamine with Enhanced Stability
- Dual Formulation of Atropine/Scopolamine with Enhanced Stability
- Dual Formulation of Atropine and Scopolamine with Enhanced Stability
Research funding history
994 SBIR/STTR records share this UEI (1991–2026). Reported award amounts total $336,438,763. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Defense, National Aeronautics and Space Administration, Department of Energy, Department of Health and Human Services, National Science Foundation, Environmental Protection Agency